151 related articles for article (PubMed ID: 30140714)
1. An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype.
Weber L; Poletti V; Magrin E; Antoniani C; Martin S; Bayard C; Sadek H; Felix T; Meneghini V; Antoniou MN; El-Nemer W; Mavilio F; Cavazzana M; Andre-Schmutz I; Miccio A
Mol Ther Methods Clin Dev; 2018 Sep; 10():268-280. PubMed ID: 30140714
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by
Koniali L; Flouri C; Kostopoulou MI; Papaioannou NY; Papasavva PL; Naiisseh B; Stephanou C; Demetriadou A; Sitarou M; Christou S; Antoniou MN; Kleanthous M; Patsali P; Lederer CW
Cells; 2023 Dec; 12(24):. PubMed ID: 38132168
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease.
Poletti V; Urbinati F; Charrier S; Corre G; Hollis RP; Campo Fernandez B; Martin S; Rothe M; Schambach A; Kohn DB; Mavilio F
Mol Ther Methods Clin Dev; 2018 Dec; 11():167-179. PubMed ID: 30533448
[TBL] [Abstract][Full Text] [Related]
4. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.
Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A
Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541
[TBL] [Abstract][Full Text] [Related]
5. β-globin gene transfer to human bone marrow for sickle cell disease.
Romero Z; Urbinati F; Geiger S; Cooper AR; Wherley J; Kaufman ML; Hollis RP; de Assin RR; Senadheera S; Sahagian A; Jin X; Gellis A; Wang X; Gjertson D; Deoliveira S; Kempert P; Shupien S; Abdel-Azim H; Walters MC; Meiselman HJ; Wenby RB; Gruber T; Marder V; Coates TD; Kohn DB
J Clin Invest; 2013 Jul; 123(8):3317-30. PubMed ID: 23863630
[TBL] [Abstract][Full Text] [Related]
6. A novel high-titer, bifunctional lentiviral vector for autologous hematopoietic stem cell gene therapy of sickle cell disease.
Hart KL; Liu B; Brown D; Campo-Fernandez B; Tam K; Orr K; Hollis RP; Brendel C; Williams DA; Kohn DB
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101254. PubMed ID: 38745893
[TBL] [Abstract][Full Text] [Related]
7. Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies.
Brusson M; Chalumeau A; Martinucci P; Romano O; Felix T; Poletti V; Scaramuzza S; Ramadier S; Masson C; Ferrari G; Mavilio F; Cavazzana M; Amendola M; Miccio A
Mol Ther Nucleic Acids; 2023 Jun; 32():229-246. PubMed ID: 37090420
[TBL] [Abstract][Full Text] [Related]
8. Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements.
Morgan RA; Unti MJ; Aleshe B; Brown D; Osborne KS; Koziol C; Ayoub PG; Smith OB; O'Brien R; Tam C; Miyahira E; Ruiz M; Quintos JP; Senadheera S; Hollis RP; Kohn DB
Mol Ther; 2020 Jan; 28(1):328-340. PubMed ID: 31628051
[TBL] [Abstract][Full Text] [Related]
9. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells.
Oh IH; Fabry ME; Humphries RK; Pawliuk R; Leboulch P; Hoffman R; Nagel RL; Eaves C
Exp Hematol; 2004 May; 32(5):461-9. PubMed ID: 15145214
[TBL] [Abstract][Full Text] [Related]
10. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
[TBL] [Abstract][Full Text] [Related]
11. Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression.
Maina N; Zhong L; Li X; Zhao W; Han Z; Bischof D; Aslanidi G; Zolotukhin S; Weigel-Van Aken KA; Rivers AE; Slayton WB; Yoder MC; Srivastava A
Hum Gene Ther; 2008 Apr; 19(4):365-75. PubMed ID: 18399730
[TBL] [Abstract][Full Text] [Related]
12. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
[TBL] [Abstract][Full Text] [Related]
13. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients.
Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C
Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice.
Everette KA; Newby GA; Levine RM; Mayberry K; Jang Y; Mayuranathan T; Nimmagadda N; Dempsey E; Li Y; Bhoopalan SV; Liu X; Davis JR; Nelson AT; Chen PJ; Sousa AA; Cheng Y; Tisdale JF; Weiss MJ; Yen JS; Liu DR
Nat Biomed Eng; 2023 May; 7(5):616-628. PubMed ID: 37069266
[TBL] [Abstract][Full Text] [Related]
15. PGE2 and Poloxamer Synperonic F108 Enhance Transduction of Human HSPCs with a β-Globin Lentiviral Vector.
Masiuk KE; Zhang R; Osborne K; Hollis RP; Campo-Fernandez B; Kohn DB
Mol Ther Methods Clin Dev; 2019 Jun; 13():390-398. PubMed ID: 31024981
[TBL] [Abstract][Full Text] [Related]
16. A chimeric HS4-SAR insulator (IS2) that prevents silencing and enhances expression of lentiviral vectors in pluripotent stem cells.
Benabdellah K; Gutierrez-Guerrero A; Cobo M; Muñoz P; Martín F
PLoS One; 2014; 9(1):e84268. PubMed ID: 24400083
[TBL] [Abstract][Full Text] [Related]
17. Beta-globin locus control region HS2 and HS3 interact structurally and functionally.
Jackson DA; McDowell JC; Dean A
Nucleic Acids Res; 2003 Feb; 31(4):1180-90. PubMed ID: 12582237
[TBL] [Abstract][Full Text] [Related]
18. βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for
Demirci S; Gudmundsdottir B; Li Q; Haro-Mora JJ; Nassehi T; Drysdale C; Yapundich M; Gamer J; Seifuddin F; Tisdale JF; Uchida N
Mol Ther Methods Clin Dev; 2020 Jun; 17():912-921. PubMed ID: 32405513
[TBL] [Abstract][Full Text] [Related]
19. The interaction between the human beta-globin locus control region and nuclear matrix.
Zhang SB; Qian RL
Cell Res; 2002 Dec; 12(5-6):411-6. PubMed ID: 12528900
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease.
Urbinati F; Wherley J; Geiger S; Fernandez BC; Kaufman ML; Cooper A; Romero Z; Marchioni F; Reeves L; Read E; Nowicki B; Grassman E; Viswanathan S; Wang X; Hollis RP; Kohn DB
Cytotherapy; 2017 Sep; 19(9):1096-1112. PubMed ID: 28733131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
